Method for amelioration of insulin resistance

Abstract

A method is disclosed utilizing the administration of extended release L-tri-iodothyronine in order to ameliorate insulin resistance. In other embodiments extended release L-tri-iodothyronine is combined with a biguanide and/or a thiazolidinedione and/or an inhibitor of the endoplasmic reticulum integrated stress response to provide a multi-targeted and synergistic approach to ameliorate insulin resistance.

What is claimed is: 
     
         1 . A method for preventing or treating insulin resistance in the cells of a human patient, the method comprising the steps of: a) providing L-tri-iodothyronine in an extended release formulation; and b) administering said extended release formulation to a human patient. 
     
     
         2 . The method of  claim 1  wherein L-thyroxine is added to the formulation. 
     
     
         3 . The method of  claim 1  wherein a member of the biguanide class of antidiabetic drugs is added to the formulation. 
     
     
         4 . The method of  claim 1  wherein a member of the thiazolidinedione class of antidiabetic drugs is added to the formulation. 
     
     
         5 . The method of  claim 1  wherein a member of the class of endoplasmic reticulum integrated stress response inhibitors is added to the formulation. 
     
     
         6 . A pharmaceutical formulation for preventing or treating insulin resistance in a human patient comprising L-tri-iodothyronine, a biguanide, and a thiazolidinedione 
     
     
         7 . A pharmaceutical formulation of  claim 6  further comprising L-thyroxine. 
     
     
         8 . A pharmaceutical formulation of  claim 6 , wherein the biguanide is omitted from the formulation. 
     
     
         9 . A pharmaceutical formulation of  claim 6 , wherein the thiazolidinedione is omitted from the formulation. 
     
     
         10 . A pharmaceutical formulation of  claim 6  further comprising a drug which is a member of the class of endoplasmic reticulum integrated stress response inhibitors. 
     
     
         11 . A method for preventing or treating insulin resistance in a human patient, the method comprising the steps of: a) providing a drug from the class of endoplasmic reticulum integrated stress response inhibitors in an appropriate formulation; and b) administering said formulation to a human patient. 
     
     
         12 . The method of  claim 11  further comprising including extended release L-tri-iodothyronine in the formulation. 
     
     
         13 . The method of  claim 11  further comprising including L-thyroxine in the formulation. 
     
     
         14 . The method of  claim 11  further comprising including a biguanide in the formulation. 
     
     
         15 . The method of  claim 11  further comprising including a thiazolidinedione in the formulation.